Elutia 過去の業績
過去 基準チェック /06
Elutiaの収益は年間平均-3%の割合で減少していますが、 Biotechs業界の収益は年間 増加しています。収益は年間33.8% 24.8%割合で 減少しています。
主要情報
-3.01%
収益成長率
26.66%
EPS成長率
| Biotechs 業界の成長 | 17.04% |
| 収益成長率 | -24.78% |
| 株主資本利益率 | -97.12% |
| ネット・マージン | -175.64% |
| 前回の決算情報 | 31 Mar 2026 |
最近の業績更新
Recent updates
ナラティブの更新 • Mar 04
ELUT: Listing Compliance Recovery Will Support Future Reconstructive Portfolio Upside
Analysts have adjusted their price target on Elutia to reflect updated views on profitability, with a lower assumed profit margin and a higher future P/E estimate shaping the new valuation in dollar terms. What's in the News Elutia received a written notice from Nasdaq on December 23, 2025 stating that it is not in compliance with the minimum market value of listed securities requirement of $35 million under Nasdaq Listing Rule 5550(b)(2) (Key Developments).ナラティブの更新 • Feb 18
ELUT: Listing Compliance Progress Will Support Future Reconstructive Portfolio Upside
Analysts have revised their price target on Elutia to $3.50, maintaining their fair value estimate while updating assumptions on the discount rate, revenue growth, profit margin, and future P/E to align with their current assessment of the company’s risk and earnings profile. What's in the News Elutia received a written notice from Nasdaq stating that it is not in compliance with the minimum market value of listed securities requirement of $35m under Listing Rule 5550(b)(2).分析記事 • Feb 15
Elutia Inc. (NASDAQ:ELUT) Surges 28% Yet Its Low P/S Is No Reason For Excitement
Elutia Inc. ( NASDAQ:ELUT ) shares have continued their recent momentum with a 28% gain in the last month alone. But...
ナラティブの更新 • Feb 04
ELUT: Future Nasdaq Compliance Resolution Will Support Bullish Repricing Potential
Analysts have maintained their price target on Elutia at US$5.00, citing a slightly lower discount rate, a modest change in expected revenue contraction, and a small adjustment to future P/E assumptions, along with a slightly higher projected profit margin. What's in the News On December 23, 2025, Elutia received a Nasdaq notice that its market value of listed securities had been below the US$35 million minimum for 30 consecutive business days, and that it also did not meet certain shareholder equity and net income standards required for continued listing on The Nasdaq Capital Market (Nasdaq notice).ナラティブの更新 • Jan 21
ELUT: Future Nasdaq Compliance Progress Will Drive Bullish Repricing Potential
Narrative Update on Elutia Analysts have maintained their price target for Elutia at US$5.00, citing slightly lower assumed revenue growth, a modestly higher profit margin outlook, and a small adjustment to the discount rate and future P/E assumptions as key drivers behind the updated view. What's in the News On December 23, 2025, Nasdaq notified Elutia that its market value of listed securities had been below the US$35 million minimum required under Listing Rule 5550(b)(2) for 30 consecutive business days, and that the company also did not meet related shareholder equity or net income standards (Nasdaq notice).ナラティブの更新 • Jan 07
ELUT: Future Compliance Recovery Will Support Bullish Repricing Potential
Analysts have reduced their price target on Elutia by US$1.00. They cite a higher discount rate, a projected revenue decline of 7.18%, and a much higher future P/E estimate, partly offset by slightly stronger expected profit margins.ナラティブの更新 • Dec 16
ELUT: Future Listing Compliance Efforts Will Support Reconstructive Portfolio Expansion
Narrative Update on Elutia Analysts have modestly adjusted their price target on Elutia upward to reflect a slightly more constructive long term earnings and valuation outlook, nudging the fair value estimate higher by approximately $0.00 per share as updated model inputs had only a de minimis impact on the overall target. What's in the News Elutia received a notice from Nasdaq that its Class A common stock has traded below the $1.00 per share minimum bid price for 30 consecutive business days, triggering a formal deficiency notification and potential delisting process (Nasdaq listing notice).分析記事 • Dec 06
Lacklustre Performance Is Driving Elutia Inc.'s (NASDAQ:ELUT) 28% Price Drop
To the annoyance of some shareholders, Elutia Inc. ( NASDAQ:ELUT ) shares are down a considerable 28% in the last...ナラティブの更新 • Dec 02
ELUT: Recent Business Sale Will Fund Breast Reconstruction Growth Ahead
Analysts have lowered Elutia's target price from $8.00 to $6.00, citing a smaller-than-expected sale price for the BioEnvelope business. However, they note that the deal removes significant overhangs and provides full funding for Elutia's breast reconstruction segment.ナラティブの更新 • Nov 17
ELUT: Recent Business Sale Will Unlock Breast Reconstruction Focus
Narrative Update on Elutia Elutia's analyst price target has been reduced from $8 to $6 following analysts’ assessment that, although the sale of the BioEnvelope business provides significant funding, the lower-than-expected acquisition price tempers near-term expectations for the company's growth. Analyst Commentary Analysts have weighed in on the implications of Elutia's recent business developments, offering a nuanced perspective on the company's outlook.ナラティブの更新 • Nov 01
ELUT: Breast Reconstruction Funding Will Drive Long-Term Shareholder Value
Elutia's analyst price target has decreased from $8 to $6, as analysts factor in the sale of its BioEnvelope business. While this sale is seen as bittersweet, it helps eliminate notable uncertainties and secures funding for the company's breast reconstruction segment.ナラティブの更新 • Oct 17
Aging Demographics And Chronic Conditions Will Spur Healing Advances
Analysts have reduced their price target for Elutia from $8 to $6 per share, citing both the lower-than-expected sale price of its BioEnvelope business and the improved funding outlook for its core breast reconstruction segment. Analyst Commentary Recent analyst reports provide a nuanced view of Elutia's prospects following the BioEnvelope business sale.分析記事 • Oct 13
The Market Doesn't Like What It Sees From Elutia Inc.'s (NASDAQ:ELUT) Revenues Yet As Shares Tumble 30%
To the annoyance of some shareholders, Elutia Inc. ( NASDAQ:ELUT ) shares are down a considerable 30% in the last...ナラティブの更新 • Oct 03
Aging Demographics And Chronic Conditions Will Spur Healing Advances
Analysts have reduced their price target for Elutia, with recent adjustments citing a new range from $8 to $5 per share. This reflects cautious optimism about the firm's strategic divestiture and future growth prospects, despite near-term revenue challenges.ナラティブの更新 • Sep 10
Aging Demographics And Chronic Conditions Will Spur Healing Advances
Elutia's fair value estimate has been revised downward due to sharply reduced revenue growth forecasts and a significantly higher future P/E multiple, resulting in the consensus price target dropping from $6.50 to $5.50. What's in the News Elutia was selected to exhibit its EluPro Antibiotic-Eluting BioEnvelope at the Vizient Innovative Technology Exchange, providing exposure to hospital supply chain and clinical leaders.分析記事 • Aug 29
Elutia Inc.'s (NASDAQ:ELUT) Price Is Right But Growth Is Lacking After Shares Rocket 27%
Elutia Inc. ( NASDAQ:ELUT ) shareholders have had their patience rewarded with a 27% share price jump in the last...分析記事 • Aug 19
US$6.50: That's What Analysts Think Elutia Inc. (NASDAQ:ELUT) Is Worth After Its Latest Results
NasdaqCM:ELUT 1 Year Share Price vs Fair Value Explore Elutia's Fair Values from the Community and select yours Elutia...ナラティブの更新 • Aug 19
FDA Cleared EluPro Launch And Capacity Expansion Will Unlock Opportunity
Despite a substantial increase in consensus revenue growth forecasts and a sharply lower future P/E, Elutia’s consensus analyst price target has been reduced from $7.50 to $6.50. What's in the News Elutia published a study showing its antibiotic-eluting CIED biologic envelope, EluPro, controls inflammation, supports vascularization, and promotes higher growth factor release, potentially reducing scarring and infection risks in implantable cardiac device patients.分析記事 • Jun 18
Revenues Working Against Elutia Inc.'s (NASDAQ:ELUT) Share Price
With a price-to-sales (or "P/S") ratio of 3.1x Elutia Inc. ( NASDAQ:ELUT ) may be sending very bullish signals at the...
新しいナラティブ • Apr 06
FDA Cleared EluPro Launch And Capacity Expansion Will Unlock Opportunity
EluPro's FDA clearance and market entry against Medtronic's TYRX could drive significant revenue growth in the antibiotic-eluting envelope space.分析記事 • Jan 04
Elutia Inc. (NASDAQ:ELUT) Not Doing Enough For Some Investors As Its Shares Slump 27%
Elutia Inc. ( NASDAQ:ELUT ) shares have had a horrible month, losing 27% after a relatively good period beforehand...分析記事 • Nov 20
Elutia Inc. (NASDAQ:ELUT) Held Back By Insufficient Growth Even After Shares Climb 26%
Elutia Inc. ( NASDAQ:ELUT ) shareholders would be excited to see that the share price has had a great month, posting a...分析記事 • Jun 28
Elutia Inc.'s (NASDAQ:ELUT) Share Price Boosted 28% But Its Business Prospects Need A Lift Too
Elutia Inc. ( NASDAQ:ELUT ) shares have continued their recent momentum with a 28% gain in the last month alone...分析記事 • Mar 10
News Flash: 2 Analysts Think Elutia Inc. (NASDAQ:ELUT) Earnings Are Under Threat
One thing we could say about the analysts on Elutia Inc. ( NASDAQ:ELUT ) - they aren't optimistic, having just made a...分析記事 • Feb 21
Elutia Inc.'s (NASDAQ:ELUT) Share Price Is Matching Sentiment Around Its Revenues
You may think that with a price-to-sales (or "P/S") ratio of 1.5x Elutia Inc. ( NASDAQ:ELUT ) is definitely a stock...収支内訳
収支内訳
Elutia の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
| 日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
|---|---|---|---|---|
| 31 Mar 26 | 12 | -22 | 22 | 5 |
| 31 Dec 25 | 12 | -16 | 21 | 4 |
| 30 Sep 25 | 22 | -25 | 28 | 4 |
| 30 Jun 25 | 22 | -22 | 29 | 4 |
| 31 Mar 25 | 24 | -40 | 30 | 4 |
| 31 Dec 24 | 14 | -45 | 23 | 3 |
| 30 Sep 24 | 18 | -53 | 24 | 4 |
| 30 Jun 24 | 20 | -65 | 24 | 4 |
| 31 Mar 24 | 25 | -49 | 27 | 4 |
| 31 Dec 23 | 25 | -41 | 27 | 4 |
| 30 Sep 23 | 25 | -32 | 28 | 5 |
| 30 Jun 23 | 25 | -35 | 31 | 6 |
| 31 Mar 23 | 19 | -38 | 33 | 7 |
| 31 Dec 22 | 24 | -36 | 34 | 8 |
| 30 Sep 22 | 28 | -39 | 34 | 9 |
| 30 Jun 22 | 34 | -37 | 34 | 10 |
| 31 Mar 22 | 46 | -28 | 33 | 10 |
| 31 Dec 21 | 47 | -25 | 33 | 9 |
| 30 Sep 21 | 49 | -21 | 33 | 8 |
| 30 Jun 21 | 49 | -23 | 32 | 7 |
| 31 Mar 21 | 46 | -26 | 29 | 6 |
| 31 Dec 20 | 43 | -25 | 28 | 6 |
| 30 Sep 20 | 42 | -23 | 28 | 5 |
| 30 Jun 20 | 42 | -16 | 28 | 4 |
| 31 Mar 20 | 43 | -13 | 27 | 3 |
| 31 Dec 19 | 43 | -12 | 26 | 2 |
| 31 Dec 18 | 39 | -12 | 22 | 2 |
質の高い収益: ELUTは現在利益が出ていません。
利益率の向上: ELUTは現在利益が出ていません。
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: ELUTは利益が出ておらず、過去 5 年間で損失は年間3%の割合で増加しています。
成長の加速: ELUTの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。
収益対業界: ELUTは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 43% ) と比較することは困難です。
株主資本利益率
高いROE: ELUTは現在利益が出ていないため、自己資本利益率 ( -97.12% ) はマイナスです。
総資産利益率
使用総資本利益率
過去の好業績企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/26 22:03 |
| 終値 | 2026/05/26 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Elutia Inc. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。6
| アナリスト | 機関 |
|---|---|
| Brandon Folkes | Cantor Fitzgerald & Co. |
| Ross Osborn | Cantor Fitzgerald & Co. |
| Frank Takkinen | Lake Street Capital Markets, LLC |